Floatz logo

Cediranib

Adult B Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Adult B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
Mayo Clinic
Phase 3BBB
Cytosin-Arabinosid
Massachusetts General Hospital
Phase 3BBB
METHOTREXATE
Massachusetts General Hospital
Phase 3BBB

View all 28 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →